Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.79 |
| ▸ | KDM6B | O15054 | 1/20 | 0.62 |
| ▸ | KDM6A | O15550 | 1/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932612 | 0.88 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6A | |
| SCHEMBL1378665 | 0.84 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6APIK3CA | |
| SCHEMBL4444923 | 0.83 | ESR1 (0.78) | ESR1ESR2KDM6BKDM6APIK3CA | |
| SCHEMBL3932428 | 0.79 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6A | |
| SCHEMBL3933889 | 0.79 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6APIK3CA | |
| SCHEMBL30900831 | 0.78 | KDM6B (0.79) | ESR1ESR2KDM6BKDM6AMEN1 | |
| SCHEMBL17654013 | 0.78 | KDM6B (0.79) | ESR1ESR2KDM6BKDM6AMEN1 | |
| SCHEMBL1375754 | 0.78 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6APIK3CA | |
| SCHEMBL9115528 | 0.78 | ESR1 (0.65) | ESR1ESR2KDM6BKDM6APIK3CA | |
| SCHEMBL1377583 | 0.77 | ESR1 (1.00) | ESR1ESR2KDM6BKDM6APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-20030171412-A1 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | WYETH | 2003-09-11 | — | — | US | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20050272786-A1 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | WYETH (US) | 2005-12-08 | — | — | US | disclosed |
| US-6960607-B2 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | WYETH (US) | 2005-11-01 | — | — | US | disclosed |
| US-20030171412-A1 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | WYETH | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171412-A1 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR1 1/4885ESR2 2/4885KDM6B 2343/4885 |
| US-20050272786-A1 | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents | ESR1, ESRRA, ESR2 | ESR1 1/4885ESR2 3/4885KDM6B 1873/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR1 4/4885ESR2 5/4885KDM6B 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.